August 7, 2025Blood ResearchOpen Access

Impact of CD34+ cell dose on outcomes of haploidentical peripheral blood stem cell transplantation in acute leukemia

View Full Paper

Ask AI

Bookmark

Authors

HCHaerim ChungUniversity of North Carolina at Chapel Hill HKHye Won KookYonsei University HCHyunsoo ChoSeoul National University

Discussion

Member takes

Implication

Retrospective analysis reveals that high CD34+ cell doses adversely affect overall survival and non-relapse mortality in acute leukemia patients undergoing haploidentical PBSCT.

Key Points

Higher CD34+ cell doses are linked to poorer overall survival in patients with acute leukemia after haplo-PBSCT.
The study analyzed 81 patients over a decade, comparing outcomes based on CD34+ cell dose thresholds.
Multivariate analysis identified high CD34+ cell doses as a significant factor for increased non-relapse mortality.
Finding the right balance of graft cell dose is crucial for improving clinical outcomes in transplantation.

Cite This Study

Chung et al. (2025) studied this question.

synapsesocial.com/papers/689dfe88d61984b91e13ba4f https://doi.org/10.1007/s44313-025-00091-5

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals that high CD34+ cell doses adversely affect overall survival and non-relapse mortality in acute leukemia patients undergoing haploidentical PBSCT.

Impact of CD34+ cell dose on outcomes of haploidentical peripheral blood stem cell transplantation in acute leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Impact of CD34+ cell dose on outcomes of haploidentical peripheral blood stem cell transplantation in acute leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider